NEWS

 Recently, good news came from the State Intellectual Property Office. Biosino Beijing Enterprises applied for "Viral Genome Nucleic Acid Extraction Kit, Methods and Applications", "A Primer Combination, Kit and Detection Method for Detecting MTHFR Gene Polymorphisms" and "A Group B Streptococcus Nucleic Acid Detection Kit and its Detection Method" and "Preparation and Application of a Latex Turbidimetric Method for Determining C Anti-Protein Detection Reagent" have been authorized, and scientific and technological research and development has achieved great results again, once again highlighting Biosino's North Control the innovative ability to make breakthroughs and stand out from the crowd.

The invention relates to the technical field of nucleic acid extraction, and specifically discloses a viral genome nucleic acid extraction kit, method and application. The kit includes lysis buffer and binding buffer. The kit and detection method do not require sample pretreatment and can directly extract viral gene nucleic acid with high efficiency and high quality. 640

The present invention relates to the field of molecular detection, and in particular, to a primer combination, a kit and a detection method for detecting MTHFR gene polymorphism. The polymorphism of the MTHFR gene can be determined quickly and accurately. This is of great significance in the field of detecting MTHFR genes.

The invention relates to a Group B Streptococcus nucleic acid detection kit and a detection method thereof. When using the kit of the present invention to detect Group B Streptococcus nucleic acid, it has high specificity and can detect all serotypes of Group B Streptococcus; it has strong anti-pollution ability and can effectively reduce residual amplification products and avoid false positive results; The detection speed is fast and reproducible, and it can qualitatively detect group B streptococcus nucleic acid in reproductive tract secretions and rectal secretion samples of perinatal pregnant women.

The invention relates to the preparation and application of a latex turbidimetric method for measuring C-antiprotein detection reagents, and belongs to the field of in vitro diagnostic detection reagents. The CRP antibody-small particle size latex microspheres and the CRP antibody-large particle size latex microspheres provided by the present invention can be used to detect C-reactive protein in the full range, and the detection results have high sensitivity and specificity.

In recent years, Biosino Beijing Enterprises has accelerated the pace of high-tech innovation and the transformation of scientific research results, continuously improved the company's core competitiveness, and provided strong scientific and technological support for the company's high-quality development. In 2022, it won the "Anti-Chylointerference Uric Acid Determination Kit" and "One "A kit and application for measuring glucose content", "A kit and method for detecting retinol-binding protein" and many other patent authorizations. The award of the honor stems from the continuous innovation spirit of Biosino people based on innovative research and development and determination to move forward. It is also the best interpretation of "the sharp edge of a sword comes from sharpening, and the fragrance of plum blossoms comes from the bitter cold", marking Biosino Beijing Enterprises' technological innovation and independent knowledge. Property rights have reached a higher level.

Biosino Beijing Enterprises focuses on the research and development, production, sales and service of in vitro diagnostic products. Its products cover biochemistry, immunity, molecular diagnosis, flow cytometry, mass spectrometry, clinical nutrition and other fields. It has 266 medical device product registration certificates and its products are sold to 50 countries around the world. Multiple countries and regions. Through years of experience accumulation and technical hard work in the IVD industry, Biosino has obtained more than 70 patents, software, trademarks, etc., reaching a high level in the same industry, fully demonstrating Biosino's R&D strength and innovation capabilities.

In the future, Biosino Beijing Enterprises will continue to forge ahead, strengthen the protection and application of intellectual property rights, accelerate technological innovation, and inject a "stimulant" into the company's leap-forward development.